Anthony Claude Antonelli
Research Subjects
Anthony Claude Antonelli has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Gil Redelman-Sidi
Division of Infectious Diseases; Memorial Sloan Kettering Cancer Center; New York
21 shared publications - Michael Stephen Glickman
Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
21 shared publications - Anna Binyamin
Immunology Program, Sloan Kettering Institute, New York, New York
20 shared publications - Achim A. Jungbluth
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
19 shared publications - Hikmat Al-Ahmadie
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
19 shared publications - James Bean
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
19 shared publications
Latest Publications
- Open Access
Predictive in vitro profiling of LNP-induced innate immune response using an iPSC-derived monocyte model
Lipid nanoparticles (LNPs) are a powerful drug delivery platform advancing vaccines and gene therapies. While their efficacy and safety has been found to be closely linked to innate immune activation, current in vitro models are unable to predict immune responses reliably. Conventional models, such as PBMCs, are limited by donor variability and inconsistent sensitivity. To address this, we developed a cytokine profiling platform using induced pluripotent stem cell (iPSC)-derived monocytes (iMonocytes), a physiologically relevant innate immune cell type that plays a key role in immune surveillance and inflammation. iPSCs provide a renewable, uniform monocyte source for consistent, high-sensitivity LNP screening. When tested with LNPs of graded immunostimulatory potency, iMonocytes showed improved reproducibility and strong correlation with in vivo cytokine responses. This platform enables evaluation of cargo- and dose-dependent effects, providing a robust and scalable tool for preclinical assessment and rational design of LNP therapeutics.
Open AccessPredictive in vitro profiling of LNP-induced innate immune response using an iPSC-derived monocyte model
Lipid nanoparticles (LNPs) are a powerful drug delivery platform advancing vaccines and gene therapies. While their efficacy and safety has been found to be closely linked to innate immune activation, current in vitro models are unable to predict immune responses reliably. Conventional models, such as PBMCs, are limited by donor variability and inconsistent sensitivity. To address this, we developed a cytokine profiling platform using induced pluripotent stem cell (iPSC)-derived monocytes (iMonocytes), a physiologically relevant innate immune cell type that plays a key role in immune surveillance and inflammation. iPSCs provide a renewable, uniform monocyte source for consistent, high-sensitivity LNP screening. When tested with LNPs of graded immunostimulatory potency, iMonocytes showed improved reproducibility and strong correlation with in vivo cytokine responses. This platform enables evaluation of cargo- and dose-dependent effects, providing a robust and scalable tool for preclinical assessment and rational design of LNP therapeutics.
- Open Access
Microbial cancer immunotherapy reprograms hematopoiesis to enhance anti-tumor immunity
Summary: Mycobacterium bovis BCG is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC-reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder in both mice and humans reprograms HSPCs to amplify myelopoiesis and functionally enhance myeloid cell antigen presentation pathways. Reconstitution of naive mice with HSPCs from bladder BCG-treated mice enhances anti-tumor immunity and tumor control, increases intratumor dendritic cell infiltration, reprograms pro-tumorigenic neutrophils, and synergizes with checkpoint blockade. We conclude that bladder BCG acts systemically, reprogramming HSPC-encoded innate immunity, highlighting the broad potential of modulating HSPC phenotypes to improve tumor immunity. Graphical
Open AccessMicrobial cancer immunotherapy reprograms hematopoiesis to enhance anti-tumor immunity
Summary: Mycobacterium bovis BCG is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC-reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder in both mice and humans reprograms HSPCs to amplify myelopoiesis and functionally enhance myeloid cell antigen presentation pathways. Reconstitution of naive mice with HSPCs from bladder BCG-treated mice enhances anti-tumor immunity and tumor control, increases intratumor dendritic cell infiltration, reprograms pro-tumorigenic neutrophils, and synergizes with checkpoint blockade. We conclude that bladder BCG acts systemically, reprogramming HSPC-encoded innate immunity, highlighting the broad potential of modulating HSPC phenotypes to improve tumor immunity. Graphical
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II
Supplementary Table from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II